SIH Partners’s Pacific Biosciences PACB Stock Holding History

SIH Partners’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-91,128	Closed	-$108K	–	269
2025 Q1	$108K	Buy	+91,128	New	+$140K	﹤0.01%	240

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIH Partners's PACB Position: Q2 2025 in Review

SIH Partners sold out of Pacific Biosciences (PACB) in Q2 2025, closing a stake of 91,128 shares — an estimated $108K sold.

SIH Partners first reported a position in PACB in Q1 2025 and held it in 1 quarter. The position peaked at $108K in Q1 2025. 207 funds tracked by Wall St. Rank hold PACB as of Q2 2025.

SIH Partners reported no remaining Pacific Biosciences position as of Q2 2025 after selling out during the quarter.
SIH Partners sold 91,128 Pacific Biosciences shares in Q2 2025, an estimated $108K.
SIH Partners first reported a position in Pacific Biosciences in Q1 2025 and held it in 1 quarter.
SIH Partners's Pacific Biosciences position peaked at $108K in Q1 2025.
207 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2025.

Based on SIH Partners's 13F filing for Q2 2025, filed 14 Aug 2025.